文献速递消化内镜消化道肿瘤与早癌

口服亚甲蓝制剂用于结肠镜筛查的疗效

Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy.
PubMed 文献 · Gastroenterology · 2019-02-10

这项3期试验纳入1205例拟行结直肠癌筛查或监测结肠镜的患者,随机给予200 mg口服亚甲蓝制剂(MB-MMX)、安慰剂或100 mg MB-MMX。200 mg MB-MMX组腺瘤检出率(56.29%)高于安慰剂组(47.81%)(OR 1.46;95%CI 1.09-1.96),非息肉样病变和≤5 mm腺瘤检出比例亦更高,非肿瘤性息肉切除率两组无显著差异。

要点

  • 200 mg口服亚甲蓝制剂使腺瘤检出率较安慰剂绝对提高8.5%。
  • 非息肉样病变检出比例MB-MMX组43.92% vs 安慰剂组35.07%(OR 1.66)。
  • ≤5 mm腺瘤检出比例MB-MMX组37.11% vs 安慰剂组30.90%(OR 1.36)。

核心结论

  • 在拟行筛查或监测结肠镜的患者中,200 mg MB-MMX较安慰剂使腺瘤检出率绝对提高8.5%,且未增加非肿瘤性病变的切除。

研究设计与样本

  • 3期研究,2013年12月至2016年10月在欧洲和美国的20个中心纳入1205例50-75岁拟行结直肠癌筛查或监测结肠镜的患者。
  • 患者按2:2:1随机分配至200 mg MB-MMX组、安慰剂组或100 mg MB-MMX组(100 mg组仅用于设盲)。
  • MB-MMX与安慰剂片剂均联合4 L聚乙二醇肠道准备给药,随后由经验丰富的内镜医师行结肠镜并集中双读。

主要发现

  • 腺瘤检出率:200 mg MB-MMX组273/485例(56.29%)vs 安慰剂组229/479例(47.81%)(OR 1.46;95%CI 1.09-1.96)。
  • 非息肉样病变患者比例:200 mg MB-MMX组213/485例(43.92%)vs 安慰剂组168/479例(35.07%)(OR 1.66;95%CI 1.21-2.26)。
  • ≤5 mm腺瘤患者比例:200 mg MB-MMX组180/485例(37.11%)vs 安慰剂组148/479例(30.90%)(OR 1.36;95%CI 1.01-1.83)。
  • 息肉样病变或更大病变的检出两组间无差异。
  • 非肿瘤性病变的假阳性率(非肿瘤性息肉切除率):200 mg MB-MMX组83/356例(23.31%)vs 安慰剂组97/326例(29.75%),两组无显著差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Topically applied methylene blue dye chromoendoscopy is effective in improving detection of colorectal neoplasia. When combined with a pH- and time-dependent multimatrix structure, a per-oral methylene blue formulation (MB-MMX) can be delivered directly to the colorectal mucosa. METHODS: We performed a phase 3 study of 1205 patients scheduled for colorectal cancer screening or surveillance colonoscopies (50-75 years old) at 20 sites in Europe and the United States, from December 2013 through October 2016. Patients were randomly assigned to groups given 200 mg MB-MMX, placebo, or 100 mg MB-MMX (ratio of 2:2:1). The 100-mg MB-MMX group was included for masking purposes. MB-MMX and placebo tablets were administered with a 4-L polyethylene glycol-based bowel preparation. The patients then underwent colonoscopy by an experienced endoscopist with centralized double-reading. The primary endpoint was the proportion of patients with 1 adenoma or carcinoma (adenoma detection rate [ADR]). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) for differences in detection between the 200-mg MB-MMX and placebo groups. False-positive (resection rate for non-neoplastic polyps) and adverse events were assessed as secondary endpoints. RESULTS: The ADR was higher for the MB-MMX group (273 of 485 patients, 56.29%) than the placebo group (229 of 479 patients, 47.81%) (OR 1.46; 95% CI 1.09-1.96). The proportion of patients with nonpolypoid lesions was higher in the MB-MMX group (213 of 485 patients, 43.92%) than the placebo group (168 of 479 patients, 35.07%) (OR 1.66; 95% CI 1.21-2.26). The proportion of patients with adenomas ≤5 mm was higher in the MB-MMX group (180 of 485 patients, 37.11%) than the placebo group (148 of 479 patients, 30.90%) (OR 1.36; 95% CI 1.01-1.83), but there was no difference between groups in detection of polypoid or larger lesions. The false-positive rate did not differ significantly between groups (83 [23.31%] of 356 patients with non-neoplastic lesions in the MB-MMX vs 97 [29.75%] of 326 patients with non-neoplastic lesions in the placebo group). Overall, 0.7% of patients had severe adverse events but there was no significant difference between groups. CONCLUSIONS: In a phase 3 trial of patients undergoing screening or surveillance colonoscopies, we found MB-MMX led to an absolute 8.5% increase in ADR, compared with placebo, without increasing the removal of non-neoplastic lesions. Clinicaltrials.gov no: NCT01694966.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Repici A, Wallace MB, East JE, et al. Efficacy of Per-oral Methylene Blue Formulation for Screening Colonoscopy. Gastroenterology. 2019. PMID: 30742834. doi:10.1053/j.gastro.2019.02.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。